| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MED29 |
| Uniprot No | Q9NX70 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-221aa |
| 活性数据 | MLKSNGERRSRNALPAVYARKMAASQQQASAASSAAGVSGPSSAGGPGPQQQPQPPAQLVGPAQSGLLQQQQQDFDPVQRYKMLIPQLKESLQTLMKVAAQNLIQNTNIDNGQKSSDGPIQRFDKCLEEFYALCDQLELCLRLAHECLSQSCDSAKHSPTLVPTATKPDAVQPDSLPYPQYLAVIKAQISCAKDIHTALLDCANKVTGKTPAPPAGPGGTL |
| 分子量 | 49.9 KDa |
| 蛋白标签 | GST-tag at N-terminal |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人MED29蛋白的参考文献示例(注：文献信息为虚构概括，建议通过实际数据库查询真实文献)：
---
1. **文献名称**: *"Cloning and Functional Characterization of Recombinant Human MED29 in Transcriptional Regulation"*
**作者**: Zhang L, et al.
**摘要**: 本研究成功克隆并表达了重组人MED29蛋白，证实其作为中介体复合体亚基与RNA聚合酶II相互作用，在体外模型中调控特定基因启动子的转录活性。
2. **文献名称**: *"Structural Analysis of MED29 Reveals Its Role in Mediator Complex Assembly"*
**作者**: Kumar S, et al.
**摘要**: 通过X射线晶体学解析重组人MED29蛋白的三维结构，发现其N端结构域对中介体复合体的稳定性至关重要，并揭示了与转录因子TFIID的潜在结合界面。
3. **文献名称**: *"MED29 Expression in Cancer: A Study Using Recombinant Protein-Based Screening"*
**作者**: Chen H, et al.
**摘要**: 利用重组MED29蛋白进行体外肿瘤细胞系分析，发现其过表达通过激活MAPK信号通路促进肿瘤细胞增殖，提示其作为癌症治疗靶点的可能性。
4. **文献名称**: *"Recombinant MED29 Purification and Its Interaction with Viral Transcription Factors"*
**作者**: Gómez-Ríos D, et al.
**摘要**: 开发了一种高效的重组人MED29蛋白原核表达纯化系统，并证明其在病毒感染过程中与HPV E7蛋白相互作用，调控病毒基因的转录。
---
建议通过PubMed、Web of Science或Google Scholar查询真实文献，使用关键词“recombinant human MED29”或“MEDiator complex subunit 29”。
**Background of Recombinant Human MED29 Protein**
MED29 (Mediator Complex Subunit 29) is a critical component of the evolutionarily conserved Mediator complex, a multi-protein assembly that regulates RNA polymerase II-driven transcription in eukaryotes. Acting as a molecular bridge, the Mediator complex facilitates communication between transcription factors and the basal transcriptional machinery, thereby modulating gene expression in response to developmental, environmental, or disease-related signals. MED29. specifically, contributes to the structural integrity and functional specificity of the Mediator complex. Studies suggest its involvement in diverse cellular processes, including cell cycle regulation, differentiation, and stress responses.
Recombinant human MED29 protein is produced via heterologous expression systems (e.g., *E. coli* or mammalian cells*), enabling high-purity, functional studies. Its recombinant form allows researchers to dissect MED29’s interactions within the Mediator complex, map binding partners, and explore its role in transcriptional dysregulation linked to cancers, neurodegenerative disorders, or metabolic diseases. Additionally, it serves as a tool for screening therapeutic compounds targeting Mediator-associated pathways. Advances in structural biology using recombinant MED29 have further clarified its conformational dynamics, aiding in the development of precision medicine strategies. Overall, recombinant MED29 is vital for unraveling transcriptional mechanisms and their implications in human health.
*(Note: Expression systems vary based on required post-translational modifications.)*
×
